Sign in
4

Changes in Ownership

Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-23-016039

EVP & Chief Commercial Officer sold 3,664 shares at $45.25 ($165,796)

  • EVP & Chief Commercial Officer acquired 24,663 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Harris Erik EVP & Chief Commercial Officer 2023-03-01 Grant or award +2,663 38,823 D: show line 1 in the form
Harris Erik EVP & Chief Commercial Officer 2023-03-01 Grant or award +22,000 60,823 D: show line 2 in the form
Harris Erik EVP & Chief Commercial Officer 2023-03-01 Sale −3,664 $45.25 $165,796 57,344 D: show line 3 in the form
Open-market sales · 3,664 sh · avg $45.25 · $165,796

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Harris Erik EVP & Chief Commercial Officer 2023-03-01 Grant or award · Stock Option (Right to Buy) +39,400 39,400 D: show line 4 in the form
Loading xslF345X03/doc4.xml…